Legal & General Group Plc raised its position in Amgen, Inc. (NASDAQ:AMGN) by 5.7% in the 4th quarter, HoldingsChannel reports. The fund owned 3,241,580 shares of the medical research company’s stock after purchasing an additional 174,360 shares during the period. Legal & General Group Plc’s holdings in Amgen were worth $631,039,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of AMGN. Blue Fin Capital Inc. boosted its holdings in shares of Amgen by 10.0% in the 3rd quarter. Blue Fin Capital Inc. now owns 7,449 shares of the medical research company’s stock valued at $1,544,000 after buying an additional 677 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in shares of Amgen by 6.5% in the 3rd quarter. Macquarie Group Ltd. now owns 168,607 shares of the medical research company’s stock valued at $34,952,000 after buying an additional 10,237 shares in the last quarter. Kentucky Retirement Systems bought a new stake in shares of Amgen in the 3rd quarter valued at about $7,108,000. Neuberger Berman Group LLC boosted its holdings in shares of Amgen by 3.9% in the 3rd quarter. Neuberger Berman Group LLC now owns 154,783 shares of the medical research company’s stock valued at $32,085,000 after buying an additional 5,836 shares in the last quarter. Finally, B. Riley Wealth Management Inc. bought a new stake in shares of Amgen in the 3rd quarter valued at about $296,000. 79.18% of the stock is owned by hedge funds and other institutional investors.
AMGN has been the topic of a number of recent analyst reports. Royal Bank of Canada restated a “neutral” rating and issued a price target on shares of Amgen in a report on Monday, January 14th. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a report on Monday, January 14th. Cowen restated a “buy” rating and issued a $234.00 price target on shares of Amgen in a report on Tuesday, February 26th. Cantor Fitzgerald restated a “hold” rating and issued a $221.00 price target on shares of Amgen in a report on Monday, April 1st. Finally, Mizuho set a $208.00 price target on shares of Amgen and gave the company a “buy” rating in a report on Friday, April 12th. Eleven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Amgen has an average rating of “Hold” and a consensus target price of $209.11.
Shares of Amgen stock opened at $177.47 on Friday. The company has a market capitalization of $109.31 billion, a P/E ratio of 12.32, a P/E/G ratio of 2.17 and a beta of 1.21. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36. Amgen, Inc. has a 52 week low of $165.22 and a 52 week high of $210.19.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.26 by $0.16. The firm had revenue of $6.23 billion during the quarter, compared to analyst estimates of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same period last year, the firm posted $2.89 EPS. Analysts expect that Amgen, Inc. will post 13.96 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 3.27%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is currently 40.28%.
In related news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $188.88, for a total value of $377,760.00. Following the completion of the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 6,000 shares of company stock valued at $1,144,120 over the last ninety days. 0.27% of the stock is currently owned by insiders.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: Portfolio Manager
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.